A randomized trial of JTT-751 versus sevelamer hydrochloride in patients on hemodialysis

Nephrology Dialysis Transplantation

Volumn 29, Issue 5, 2014, Pages 1053-1060

  Yokoyama, Keitaro ^a   Akiba, Takashi ^b   Fukagawa, Masafumi ^c   Nakayama, Masaaki ^d   Sawada, Kenichi ^e   Kumagai, Yuji ^f   Chertow, Glenn M ^g   Hirakata, Hideki ^h  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^c TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^e AKITA UNIVERSITY   (Japan)

^f KITASATO UNIVERSITY HOSPITAL   (Japan)

^g STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h FUKUOKA RED CROSS HOSPITAL   (Japan)

Author keywords

Clinical trial; ferric citrate; hemodialysis; hyperphosphatemia; phosphate binder

Indexed keywords

CALCIUM; FERRITIN; HEMOGLOBIN; JTT 751; PARATHYROID HORMONE; PHOSPHATE; PHOSPHATE BINDING AGENT; SEVELAMER; TRANSFERRIN; UNCLASSIFIED DRUG;

ABDOMINAL DISCOMFORT; ABDOMINAL DISTENSION; ADULT; ARTICLE; CALCIUM BLOOD LEVEL; CLINICAL EFFECTIVENESS; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; END STAGE RENAL DISEASE; FEMALE; FERRITIN BLOOD LEVEL; GASTROINTESTINAL DISEASE; HEMODIALYSIS; HUMAN; HYPERPHOSPHATEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL (TOPIC); PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

CLINICAL TRIAL; FERRIC CITRATE; HEMODIALYSIS; HYPERPHOSPHATEMIA; PHOSPHATE BINDER;

ADULT; CHELATING AGENTS; FEMALE; FERRIC COMPOUNDS; HUMANS; HYPERPHOSPHATEMIA; INTERVENTION STUDIES; JAPAN; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PARATHYROID HORMONE; POLYAMINES; RENAL DIALYSIS; YOUNG ADULT;

EID: 84899827376     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gft483     Document Type: Article

References (17)

1. Moe S, Drüeke T, Cunningham J et al., Kidney Disease Improving Global Outcomes (KDIGO). Definition, evaluation, and classification of renal os-teodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 69: 1945-1953
2. Block GA, Hulbert-Shearon TE, Levin NW et al. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31: 607-617
3. Braun J, Oldendorf M, Moshage W et al. Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis 1996; 27: 394-401
4. Sarnak MJ. Cardiovascular complications in chronic kidney disease. Am J Kidney Dis 2003; 41(5 Suppl): 11-17
5. KDOQI Clinical Practice Guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42(3 Suppl): S1-S202
6. Fukagawa M, Yokoyama K, Koiwa F et al., for CKD-MBD Guideline-Working Group, Japanese Society for Dialysis Therapy. Clinical Practice Guideline for the management of chronic kidney disease-mineral and bone disorder. Ther Apher Dial 2013; 17: 247-288
7. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group: KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009; 113: S1-130
8. Nagina A. Phosphate binders in CKD-past, present, and future. J Indian Acad Clin Med 2009; 10: 43-45
9. Sinsakul M, Sika M, Koury M et al., Collaborative Study Group. The safety and tolerability of ferric citrate as a phosphate binder in dialysis patients. Nephron Clin Pract 2012; 121: c25-c29
10. Dwyer JP, Sika M, Schulman G et al., Collaborative Study Group. Dose-response and efficacy of ferric citrate to treat hyperphosphatemia in hemodi-alysis patients: a short-term randomized trial. Am J Kidney Dis 2013; 61: 759-766
11. Iida A, Kemmochi Y, Kakimoto K et al. Ferric citrate hydrate, a new phosphate binder, prevents the complications of secondary hyperparathyroid-ism and vascular calcification. Am J Nephrol 2013; 37: 346-358
12. Yokoyama K, Hirakata H, Akiba T et al. Effect of oral JTT-751 (ferric citrate) on hyperphosphatemia in hemodialysis patients: results of a randomized, double-blind, placebo-controlled trial. Am J Nephrol 2012; 36: 478-487
13. Payne RB, Carver ME, Morgan DB. Interpretation of serum total calcium: effects of adjustment for albumin concentration on frequency of abnormal values and on detection of change in the individual. J Clin Pathol 1979; 32: 56-60
14. Tonelli M, Pannu N, Manns B. Oral phosphate binders in patients with kidney failure. N Engl J Med. 2010; 362: 1312-1324
15. Brezina B, Qunibi WY, Nolan CR. Acid loading during treatment with se-velamer hydrochloride: Mechanisms and clinical implications. Kidney Int Suppl 2004; 66: SS39-SS45
16. Drüeke TB, Parfrey PS. Summary of the KDIGO guideline on anemia and comment: reading between the (guide)line(s). Kidney Int 2012; 82: 952-960
17. Daugirdas JT, Finn WF, Emmett M et al. Frequent Hemodialysis Network Trial Group: the phosphate binder equivalent dose. Semin Dial 2011; 24: 41-49